VTVT (vTv Therapeutics) Operating Cash Flow per Share : $-5.40 (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is vTv Therapeutics Operating Cash Flow per Share?

vTv Therapeutics's operating cash flow per share for the three months ended in Sep. 2024 was $-1.18. vTv Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-5.40.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 15.70% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 35.40% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 23.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for vTv Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

VTVT' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -69.9 Med: 28.25 Max: 56.4
Current: 15.7

During the past 11 years, vTv Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 56.40% per year. The lowest was -69.90% per year. And the median was 28.25% per year.

VTVT's 3-Year OCF Growth Rate is ranked better than
62.37% of 1188 companies
in the Biotechnology industry
Industry Median: 3.85 vs VTVT: 15.70

vTv Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for vTv Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

vTv Therapeutics Operating Cash Flow per Share Chart

vTv Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-30.41

-15.28

-12.33

-8.35

-9.15

vTv Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-2.32	-1.40	-1.77	-1.05	-1.18

Competitive Comparison of vTv Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, vTv Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

vTv Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Price-to-Operating-Cash-Flow falls into.

vTv Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

vTv Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-19.081	/	2.085
	=	-9.15

vTv Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Sep. 2024 )	=	Cash Flow from Operations (Q: Sep. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2024 )
	=	-6.418	/	5.456
	=	-1.18

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.40

vTv Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of vTv Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

vTv Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » vTv Therapeutics Inc (NAS:VTVT) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

5VT0:Germany

Address

3980 Premier Drive, Suite 310, High Point, NC, USA, 27265

Website

https://www.vtvtherapeutics.com

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.

Executives

Paul J Sekhri	director, officer: President and CEO	C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Steven L. Tuch	officer: Chief Financial Officer	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
John A Fry	director	C/O DELAWARE INVESTMENTS, 2005 MARKET ST. 34TH FL., PHILADELPHIA PA 19103
Jonathan Isaacsohn	director	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Fahed Al-marzooqi	director	AL KHATEM TOWER, ABU DHABI GLOBAL MARKET, ABU DHABI C0 00000
Keith R. Harris	director	C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Hersh Kozlov	director	WOLF BLOCK SCHORR & SOLIS, 1940 RTE 70 E, CHERRY HILL NJ 08003
Howard L. Weiner	director	4170 MENDENHALL OAKS PKWY, HIGH POINT NC 27265
Chandresh Harjivan	director	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Al-nahyan Tahnoon Bin Zayed S.	10 percent owner	OFFICE 2458, FLOOR 24, AL-SILA TOWER, ABU DHABI C0 00000
G42 Investments Ai Holdings Rsc Ltd.	director, 10 percent owner	OFFICE 801, FLOOR 8, AL KHATEM TOWER, ABU DHABI C0 00000
Barry K. Brown	officer: Chief Accounting Officer	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Rich S. Nelson	director, officer: Acting Chief Executive Officer	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Ronald O Perelman	10 percent owner	35 EAST 62ND STREET, NEW YORK NY 10021
Deepa Prasad	director, officer: President and CEO	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265